Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605596 | 0.88 | ALDH1A1 (0.37) | — | |
| SCHEMBL3607136 | 0.88 | GPR119 (0.42) | NR1H2NR1H3GPR119CASP3 | |
| SCHEMBL3606120 | 0.87 | POLB (0.37) | — | |
| SCHEMBL3597127 | 0.87 | DDB1 (0.34) | NR1H2NR1H3GPR119GRM2CASP3 | |
| SCHEMBL3601055 | 0.87 | GPR119 (0.41) | NR1H2NR1H3GPR119 | |
| SCHEMBL3606731 | 0.87 | OPRM1 (0.38) | NR1H2NR1H3GPR119OPRM1GRM2 | |
| SCHEMBL3601852 | 0.86 | MAPT (0.40) | — | |
| SCHEMBL3609983 | 0.86 | ALDH1A1 (0.36) | NR1H2NR1H3 | |
| SCHEMBL3604816 | 0.85 | GPR119 (0.36) | NR1H2NR1H3GPR119CASP3 | |
| SCHEMBL3607457 | 0.85 | USP30 (0.44) | NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | NR1H2 1861/4885NR1H3 2124/4885GPR119 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.